HEXO Corp Reports Third Quarter Fiscal 2021 Financial Results
HEXO Corp. reported its 3Q21 financial results, showing total net sales increased 2% year-over-year. Key highlights include a 169% surge in non-beverage adult-use net revenues outside Quebec and a 14% growth in Ontario sales. Despite maintaining a leading position in Canada’s beverage category and a strong working capital of $182M, total net sales experienced a $10.2M decline from the prior quarter. The company announced acquisitions of 48North and Redecan, aiming to enhance its market presence. Additionally, adjusted EBITDA was ($10.78M) for the quarter.
- Total net sales rose 2% year-over-year.
- Non-beverage adult-use net revenues outside Quebec increased by 169%.
- Sales in Ontario grew by 14% sequentially.
- Maintained the number one position in the beverage category with a 46% market share.
- Strong working capital of $182M and $194M cash on hand.
- Successful launch of six new products by Truss for summer.
- Total net sales declined by $10.2M from the previous quarter.
- Non-beverage Canadian adult-use revenue decreased by 7% from 3Q20 and 29% from 2Q21.
- Operating expenses decreased only 2% from 2Q21, indicating ongoing cost challenges.
- Adjusted EBITDA decreased to ($10.78M) from $0.2M in 2Q21.
OTTAWA, June 14, 2021 (GLOBE NEWSWIRE) -- HEXO Corp. (TSX: HEXO; NYSE: HEXO) (“HEXO” or the "Company") today reported its financial results for the third quarter fiscal 2021 ended April 30, 2021 (“3Q21”). All amounts are expressed in Canadian dollars unless otherwise noted.
“At the advent of legalization, we articulated a plan to become a top three cannabis player in the Canadian adult-use market. With the acquisition of Zenabis and the announcements of intent to acquire 48North and Redecan, we are on the verge of surpassing that objective to become the no.1 licensed producer by recreational market share,” said HEXO CEO and co-founder Sebastien St-Louis. “While this was a challenging quarter, we maintained our number one position in the beverage category and increased our net sales outside of Quebec by
Key Financial & Operating Results
- Total net sales increased
2% year over year. - Total non-beverage adult-use net revenues in Canada, excluding Quebec, increased by
169% from 3Q20, while maintaining the number one position in Quebec. - Net revenue (excluding beverage) increased
14% in Ontario from 2Q21 - Maintained the number one position in the beverage category.
- Total net sales declined
$10.2M from the previous quarter. - Total net loss remained flat as compared to the previous quarter.
- Working capital remained strong at
$182M , with$194M of cash on hand as of today - Non-beverage Canadian adult-use revenue decreased by
7% from 3Q20 and declined29% from the previous quarter 2Q21 primarily as a result of a$5.2M sequential sales decline in the province of Quebec due to the specific timing of strain cultivation decisions made by the company, as well as certain production decisions in hash, which the company has since rectified and believes will result in growth within Quebec in the coming quarters - In May, Truss strengthened its share leadership of the beverage category in Canada, growing to
46% market share nationally ($ share)1 [inc. Quebec]. - With awareness of the category at an all-time high amongst potential cannabis consumers (87 percent2), Truss expects Canadians to embrace cannabis beverages throughout the summer of 2021 and beyond.
- In April, Truss announced six new products to its existing brand offering for summer. Proudly made in Belleville, Ontario, the new CBD and THC products are full of flavours inspired by the approaching summer season, as well as feedback and insights gathered from Truss’ community of consumers:
- House of Terpenes™ Valencene & Sparkling Tonic
- XMG™ Citrus and XMG™ Watermelon
- Veryvell™ Honey Green Iced Tea
- Little Victory™ Lemonade
- Mollo™ 5 Lime
- The Company elected to repay its outstanding credit facility of
$28,875 early, mitigating future interest and administrative costs. - Selling, general and administrative costs, (defined as General and administrative, plus marketing and promotion, plus research and development), decreased
8% sequentially, coming in at$14.4M , down from$15.6M in 2Q21. - Operating expenses decreased
17% from 2Q21 when adjusted for Health Canada recovery fees3 of$3.6M . - Adjusted EBITDA for the period was ($10.78M), decreased from
$0.2M in 2Q21.
Significant Subsequent Events
- Entered into a definitive agreement to acquire 48 North Cannabis Corp, offering a diversified product portfolio and accretive synergies. This transaction remains subject to customary closing approvals including regulatory and shareholders approvals, as well as approval of the plan of arrangement by the Ontario Superior Court of Justice.
- Entered into a definitive share purchase agreement to acquire Redecan, Canada’s largest private licensed producer. This transaction remains subject to customary closing approvals including regulatory and shareholders approvals.
- Closed Zenabis Global Inc. acquisition on June 1, 2021.
- Launched an at-the-market offering of C
$150m , to date approximately C$47.2M of net proceeds have been raised. - Won a dismissal (subject to plaintiffs’ appeal right) of the securities class action pending in the Commercial Division of the Supreme Court of the State of New York, New York County.
- Committed to offsetting the Company’s operational carbon emissions and the personal emissions of all 1,200 employees to become a leader in Environmental, Social, and Governance action.
Third Quarter 2021 Financial Results
| For the three months ended | For the nine months ended | ||||||
| Income Statement Snapshot | April 30, 2021 | January 31, 2021 | April 30, 2020 | April 30, 2021 | April 30, 2020 | ||
| $ | $ | $ | $ | $ | |||
| Revenue from sale of goods | 33,082 | 45,678 | 30,895 | 120,059 | 74,009 | ||
| Excise taxes | (10,482) | (12,851) | (8,817) | (35,219) | (20,516) | ||
| Net revenue from sale of goods | 22,600 | 32,827 | 22,078 | 84,840 | 53,493 | ||
| Ancillary revenue | 60 | 53 | 54 | 168 | 145 | ||
| Total revenue | 22,660 | 32,880 | 22,132 | 85,008 | 53,638 | ||
| Gross profit before adjustments1 | 5,006 | 11,688 | 8,783 | 27,075 | 18,873 | ||
| Gross profit/(loss) before fair value adjustments1 | 4,379 | 11,314 | 8,783 | 27,617 | (23,276) | ||
| Gross profit/(loss)1 | 8,816 | 18,584 | 5,730 | 45,614 | (23,260) | ||
| Operating expenses | (24,906) | (25,501) | (26,786) | (71,186) | (347,883) | ||
| Loss from operations | (16,090) | (6,917) | (21,056) | (25,572) | (371,143) | ||
| Other expenses and losses | (4,621) | (13,922) | 1,537 | (20,175) | (12,790) | ||
| Loss and comprehensive loss before tax | (20,711) | (20,839 | (19,519) | (45,747) | (383,933) | ||
| Tax recovery | – | – | – | – | 6,023 | ||
| Other comprehensive income | 3 | – | – | 3 | – | ||
| Total Net loss and comprehensive loss | (20,708) | (20,839) | (19,519) | (45,744) | (377,910) | ||
| 1 The Company has adjusted the presentation of gross profit before fair value adjustments by removing inventory and biological asset write offs and impairment losses. | |||||||
Total net revenue in 3Q21 decreased
The Company had no international medical cannabis sales due to revised prerequisite testing and an additional certification by the Israeli government which caused a delay in the Company’s ability to export. The Company has since received clearance and is now in compliance to resume these international sales.
Total net revenue for the nine months ended April 30, 2021 increased
Operating Expenses
| For the three months ended | For the nine months ended | |||||
| April 30, 2021 | January 31, 2021 | April 30, 2020 | April 30, 2021 | April 30, 2020 | ||
| $ | $ | $ | $ | $ | ||
| Selling, general and administration1 | 11,177 | 12,299 | 11,238 | 35,147 | 40,833 | |
| Marketing and promotion | 2,452 | 2,149 | 2,131 | 6,682 | 9,621 | |
| Share-based compensation | 2,715 | 5,259 | 6,171 | 10,904 | 22,237 | |
| Research and development | 730 | 1,136 | 1,017 | 2,901 | 3,962 | |
| Depreciation of property, plant and equipment | 1,612 | 1,679 | 1,566 | 4,369 | 4,890 | |
| Amortization of intangible assets | 371 | 342 | 341 | 1,043 | 3,690 | |
| Restructuring costs | 336 | 860 | 865 | 1,721 | 4,846 | |
| Impairment of property, plant and equipment | 16 | 61 | 220 | 881 | 33,004 | |
| Impairment of intangible assets | – | – | – | – | 106,189 | |
| Impairment of goodwill | – | – | – | – | 111,877 | |
| Realization of onerous contract | – | – | – | – | 3,000 | |
| Disposal of long-lived assets | – | 1,294 | 3,237 | 1,294 | 3,734 | |
| Loss/(gain) on disposal of property, plant and equipment | (19) | (14) | – | 45 | – | |
| Acquisition and transaction costs | 1,871 | 436 | – | 2,308 | – | |
| Health Canada Recovery Fee’s1 | 3,644 | – | – | 3,891 | – | |
| Total | 24,906 | 25,501 | 26,786 | 71,186 | 347,883 | |
| 1 The Company has adjusted the presentation of the Selling, General and Administrative expenses to breakdown the Health Canada Recovery Fee’s for ease of user review and identification. This presentation differs from that of the Company’s interim financial statement for the three and nine months ended April 30, 2021. | ||||||
Total operating expenses decreased
The Health Canada recovery fees will be paid annually each April and are based upon the previous fiscal year’s sales and purchases by class of cannabis and quantity purchased and sold.
Non-IFRS Measures
In this press release, reference is made to gross profit before adjustment, profit/margin before fair value adjustments, adjusted gross profit/margin, adjusted EBITDA, and revenue per gram equivalent which are not measures of financial performance under International Financial Reporting Standards (IFRS). These metrics and measures are not recognized measures under IFRS, do not have meanings prescribed under IFRS and are as a result unlikely to be comparable to similar measures presented by other companies. These measures are provided as information complementary to those IFRS measures by providing a further understanding of our operating results from the perspective of management. As such, these measures should not be considered in isolation or in lieu of a review of our financial information reported under IFRS. Definitions and reconciliations for all terms above can be found in the Company’s Management’s Discussion and Analysis for the three and nine months ended June 14, 2021, filed under the Company’s profile on SEDAR at www.sedar.com and EDGAR at www.sec.gov respectively
Conference Call
The Company will hold a conference call, June 14, 2021 to discuss these results. Sebastien St-Louis, CEO, and Trent MacDonald, CFO, will host the call starting at 8:30 a.m. Eastern. Analysts’ question and answer period will follow management’s presentation.
Date: June 14, 2021
Time: 8:30 a.m. EST
Webcast: https://event.on24.com/wcc/r/3081628/E4BE698102B436FE02D50AD0539C6797
For previous quarterly results and recent press releases, see hexocorp.com.
About HEXO Corp
HEXO is an award-winning licensed producer of innovative products for the global cannabis market. HEXO serves the Canadian recreational market with a brand portfolio including HEXO, UP Cannabis, Original Stash, Bake Sale, Namaste, and REUP brands, and the medical market in Canada, Israel and Malta. The Company also serves the Colorado market through its Powered by HEXO® strategy and Truss CBD USA, a joint-venture with Molson Coors. In the event that the previously announced transactions to acquire 48North and Redecan close, HEXO expects to be the number one cannabis products company in Canada by recreational market share. For more information, please visit www.hexocorp.com.
Forward-Looking Statements
This press release contains forward-looking information and forward-looking statements within the meaning of applicable securities laws (“forward-looking statements”). Forward-looking statements are based on certain expectations and assumptions and are subject to known and unknown risks and uncertainties and other factors that could cause actual events, results, performance and achievements to differ materially from those anticipated in these forward-looking statements. Forward-looking statements should not be read as guarantees of future performance or results. Forward-looking statements in this press release include but are not limited to the Company’s statements with respect to management’s belief that certain expenses included in operating expenses are non-recurring and related to significant changes in market conditions and the refocus of its operations on becoming Adjusted EBITDA positive.
A more complete discussion of the risks and uncertainties facing the Company appears in the Company’s Annual Information Form and other continuous disclosure filings, which are available on SEDAR at www.sedar.com and EDGAR at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements as a result of new information or future events, or for any other reason.
Investor Relations:
invest@hexo.com
www.hexocorp.com
Media Relations:
(819) 317-0526
media@hexo.com
1 To help us better understand the performance of our products in Canada, Truss developed an internal proprietary market share tracker utilizing point-of-sales data supplied by third-party data providers and data provided by government agencies.
2 Findings of a survey conducted by Truss Beverage Co. from Nov 4, 2020 to Nov 9, 2020 with a sample of 1,500 Canadian cannabis non-rejectors online who are members of the Angus Reid Forum.
3 Health Canada recovery fees are expenses based upon the previous years net sales and are realized in April.
FAQ
What were HEXO's 3Q21 financial results?
How did HEXO perform in the beverage category?
What is HEXO's adjusted EBITDA for 3Q21?
What acquisitions did HEXO announce?
What challenges did HEXO face in Quebec?
